https://www.selleckchem.com/pr....oducts/i-bet-762.htm
Current standard treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been proved effective, but it is poorly effective in refractory patients and unclear for anti-IgG4 antibody-associated CIDP. Rituximab is a B cell-depleting monoclonal antibody. It has been applied as one of the management strategies in CIDP, but its efficacy is unknown. To perform a systematic review and a meta-analysis of the efficacy of rituximab treatment in CIDP patients. Through searches in MEDLINE, PubMed, EMBASE, BIOSOS, Web of S
Me gusta
Comentario
Compartir
